Xenetic Biosciences (NASDAQ:XBIO) versus Ampio Pharmaceuticals (NYSE:AMPE) Head to Head Analysis

Xenetic Biosciences (NASDAQ:XBIO) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Valuation & Earnings

This table compares Xenetic Biosciences and Ampio Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenetic Biosciences	$2.50 million	1.47	-$4.14 million	($2.57)	-0.93
Ampio Pharmaceuticals	N/A	N/A	-$8.63 million	($11.01)	0.00

Xenetic Biosciences has higher revenue and earnings than Ampio Pharmaceuticals. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Ampio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

15.1% of Xenetic Biosciences shares are held by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are held by institutional investors. 14.7% of Xenetic Biosciences shares are held by insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and target prices for Xenetic Biosciences and Ampio Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenetic Biosciences	0	1	0	0	2.00
Ampio Pharmaceuticals	0	0	0	0	0.00

Volatility and Risk

Xenetic Biosciences has a beta of 2.3, suggesting that its share price is 130% more volatile than the S&P 500. Comparatively, Ampio Pharmaceuticals has a beta of 3.77, suggesting that its share price is 277% more volatile than the S&P 500.

Profitability

This table compares Xenetic Biosciences and Ampio Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Xenetic Biosciences	-161.63%	-49.51%	-43.99%
Ampio Pharmaceuticals	N/A	N/A	N/A

Summary

Xenetic Biosciences beats Ampio Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.